Down syndrome, also known as trisomy 21, is the most common chromosomal abnormality found in human beings. It is caused by having an extra copy of chromosome 21 which leads to developmental delays and physical impairments.

Prenatal diagnosis for Down syndrome is critical as it allows the parents to make informed decisions about the continuation of the pregnancy, and also helps the medical professionals to prepare for the delivery of the child.

: Current Diagnosis Methods

The current prenatal diagnostic methods for Down syndrome are invasive and carry the risk of miscarriage.

These methods involve chorionic villus sampling (CVS) or amniocentesis, where a sample of fetal cells is collected from the placenta or amniotic fluid for genetic testing. These tests can be done as early as the 10th week of pregnancy, but results may take a few weeks to come back.

: Non-Invasive Prenatal Testing

There have been significant advances in non-invasive prenatal testing (NIPT) over the last decade. NIPT analyzes the fetal DNA found in the pregnant woman’s blood, thus avoiding the need for invasive testing.

NIPT can be done as early as the 9th week of pregnancy and has a higher detection rate than traditional prenatal screening tests. NIPT is not diagnostic, but rather a screening test that carries a very low false-positive rate. NIPT can also detect other chromosomal abnormalities, such as Edwards syndrome and Patau syndrome.

: Cell-Free DNA Testing

Cell-free DNA testing (cfDNA) is a type of NIPT that analyzes the fetal DNA found in the mother’s blood plasma. It has a high detection rate and a low false-positive rate for Down syndrome, but is not diagnostic.

cfDNA testing can be done as early as the 7th week of pregnancy and results are usually available within a week. However, cfDNA testing is more expensive than traditional prenatal screening tests and may not be covered by insurance.

: Whole Genome Sequencing

Whole genome sequencing (WGS) is a new technology that allows for the sequencing of the entire genome of the fetus.

WGS is still in the experimental stage but has shown promising results in detecting Down syndrome as well as other chromosomal abnormalities. WGS can also detect single-gene disorders and may eventually replace the need for invasive testing. However, WGS is currently very expensive, and it may take some time before it becomes widely available.

Related Article The Global Market for Down Syndrome Prenatal Testing

: DNA Methylation

DNA methylation is a process that modifies the DNA molecule without changing the genetic code. It has been shown that DNA methylation patterns are different in individuals with Down syndrome than in typical individuals.

This has led to the development of a new non-invasive prenatal test called the epigenetic prenatal diagnosis (EPD). EPD analyzes the DNA methylation patterns in the fetus’s DNA found in the mother’s blood, and has shown promising results in detecting Down syndrome.

: Ultrasound

Ultrasound can be used as a non-invasive screening tool for Down syndrome. The ultrasound is used to measure the thickness of the nuchal translucency (NT), which is the fluid-filled space behind the fetus’s neck.

An increased NT measurement is associated with an increased likelihood of Down syndrome. However, the ultrasound screening has a high false-positive rate and does not diagnose Down syndrome.

: Integrated Prenatal Testing

Integrated prenatal testing is a combination of traditional prenatal screening tests with a follow-up amniocentesis or CVS if necessary. The traditional screening tests include a blood test and an ultrasound to measure the NT thickness.

If the screening tests show a high risk for Down syndrome, then amniocentesis or CVS is recommended. Integrated prenatal testing has a low false-positive rate and a higher detection rate than traditional screening tests alone. However, it is still an invasive test and carries a risk of miscarriage.

: Sequential Testing

Sequential testing is another combination of traditional prenatal screening tests with a follow-up NIPT. The sequential testing involves an initial blood test followed by an ultrasound to measure the NT thickness.

If the risk for Down syndrome is still high, then NIPT is recommended. Sequential testing has a lower false-positive rate than traditional screening tests alone but carries a higher cost due to the need for both screening tests and NIPT.

: Conclusion

There have been significant advances in prenatal diagnosis for Down syndrome in recent years. NIPT has become the preferred non-invasive screening tool, and other methods such as WGS and EPD have shown promising results.

Ultrasound and traditional screening tests can also be used to identify pregnancies at increased risk for Down syndrome, and integrated and sequential testing can provide a more detailed risk assessment. However, invasive testing such as amniocentesis and CVS is still necessary for a definitive diagnosis.